New drug trial aims to shrink bulging eyes
NCT ID NCT07113262
Summary
This study is testing whether an investigational drug called IBI311 can reduce eye bulging (proptosis) in people with inactive thyroid eye disease. About 111 participants will be randomly assigned to receive either IBI311 or a placebo for 24 weeks, followed by a longer follow-up period. The main goal is to see if the drug safely reduces eye protrusion by at least 2 millimeters compared to a dummy treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Medical University
RECRUITINGShenyang, Liaoning, 110801, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.